Jongphil Kim

18PUBLICATIONS
95CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)HaematologyMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jul 21, 2026
Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.

|Jul 17, 2026
A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma.

|Apr 08, 2026
Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT).

Reshma Ramlal, Jongphil Kim, Zachary Thompson

|Sep 22, 2025
Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.

Mark B Meads, Xiaohong Zhao, David Noyes

|Jul 05, 2025
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.

Jena Schmitz, Eric Gaskill, Samantha Price

|Dec 09, 2024
Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes.

Ciara L Freeman, Jerald Noble, Meghan Menges

Pageof 3

Frequent Collaborators

8 joint publications

Taiga Nishihori

7 joint publications

Nelli Bejanyan

6 joint publications

Hany Elmariah

5 joint publications

Aleksandr Lazaryan